

Charles River Laboratories International, Inc. (CRL)

NYSE; other; SIC 8731, Services-Commercial Physical & Biological Research; CIK 0001100682

Charles River Laboratories International, Inc. CRL; other	
Grade	B  second fifth of 336 graded peers percentile 31.0; sampling error 2.6 points; lower is stronger
Rank	105 of 336
Profitability	A/B  percentile 21.4
Solvency	C  percentile 55.9
Growth and financing	C  percentile 49.1
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$7.1B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 18, 2026 233 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$298.09 2026-10-08; market equity \$14.2B
Price used in grade	None



B, the elk

second fifth of its sector; letters are fifths of the 336 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B/C from Apr 21, 2019, C from Feb 21, 2020, D from Feb 21, 2025, B from Feb 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 18, 2026

This Annual Report on Form 10-K contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 21.4						
Gross profitability		not computable	27.1%			one or more required annual facts are missing
Return on invested capital		not computable	10.0%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(12.0%)	(5.9%)	21.4	506	2025-12-27
Gross margin stability, five years		not computable	2.2 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 55.9						
Twelve-month failure probability		not computable	0.04%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		1.81	2.05	42.3	386	2025-12-27
Net debt to EBITDA		4.49x	2.52x	76.5	184	2025-12-27
Interest coverage		not computable	2.18x			latest aligned inputs end 2023-12-30; latest annual assets end 2025-12-27
Current ratio		1.29x	1.32x	48.9	506	2025-12-27
Growth and financing, sleeve percentile 49.1						
Revenue growth, three-year compound		0.3%	5.1%	67.2	403	2025-12-27
Free cash flow growth, three-year compound		20.7%	8.7%	32.9	220	2025-12-27
Reinvestment rate		not computable	11.9%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(2.1%)	4.1%	74.1	438	2025-12-27
Net share issuance, one year		(3.7%)	(0.4%)	22.3	356	2026-01-24

Among 336 peers

other; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
100	Planet Fitness, Inc. (PLNT)	29.6	B	
101	Broadridge Financial Solutions, Inc. (BR)	29.9	B	
102	C. H. Robinson Worldwide, Inc. (CHRW)	30.1	B	
103	Barrett Business Services Inc. (BBSI)	30.4	B	
104	National CineMedia, Inc. (NCMI)	30.7	B	fortress
105	Charles River Laboratories International, Inc. (CRL) <	31.0	B	balance sheet
106	Century Casinos Inc. (CNTY)	31.3	B	late filer
107	Vulcan Materials Co. (VMC)	31.6	B	
108	Verra Mobility Corp. (VRRM)	31.9	B	
109	Quanta Services, Inc. (PWR)	32.2	B	
110	Brinks Co. (BCO)	32.5	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	84.2%	2.0%	95
Distance from 52-week high	(4.1%)	(26.8%)	91
EBIT to enterprise value	0.2%	4.4%	19
Free cash flow yield	3.6%	4.1%	45
Book value to price	0.20	0.34	31
Sales to price	0.28	0.70	24
Composite equity issuance, five years	(4.2%)	(8.8%)	59
Relative strength against the sector, log excess return	0.46	(0.13)	95

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-27	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$192.0M
Operating cash flow, four quarters	\$582.1M
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$245.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$25.2M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$99.5M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$42.7M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
4	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$2.1B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
5	book equity	us-gaap:StockholdersEquity	\$3.2B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$213.8M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$2.2B	2024-12-28	2026-02-18	10-K	0001100682-26-000022
8	book equity	us-gaap:StockholdersEquity	\$3.5B	2024-12-28	2026-02-18	10-K	0001100682-26-000022
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$194.6M	2024-12-28	2026-02-18	10-K	0001100682-26-000022
10	net income	us-gaap:NetIncomeLoss	-\$144.3M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$737.6M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
12	assets	us-gaap:Assets	\$7.1B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
13	assets	us-gaap:Assets	\$7.5B	2024-12-28	2026-02-18	10-K	0001100682-26-000022
14	current assets	us-gaap:AssetsCurrent	\$1.4B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
15	current liabilities	us-gaap:LiabilitiesCurrent	\$1.1B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$1.4B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
17	liabilities	us-gaap:Liabilities	\$3.9B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$403.3M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
19	operating income	us-gaap:OperatingIncomeLoss	\$617.3M	2023-12-30	2026-02-18	10-K	0001100682-26-000022
20	interest expense	us-gaap:InterestExpense	\$136.7M	2023-12-30	2024-02-14	10-K	0001100682-24-000007
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.0B	2025-12-27	2026-02-18	10-K	0001100682-26-000022
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.0B	2024-12-28	2026-02-18	10-K	0001100682-26-000022
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.1B	2023-12-30	2026-02-18	10-K	0001100682-26-000022
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.0B	2022-12-31	2025-02-19	10-K	0001100682-25-000011
25	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$219.2M	2025-12-27	2026-02-18	10-K	0001100682-26-000022
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$734.6M	2024-12-28	2026-02-18	10-K	0001100682-26-000022
27	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$233.0M	2024-12-28	2026-02-18	10-K	0001100682-26-000022
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$683.9M	2023-12-30	2026-02-18	10-K	0001100682-26-000022
29	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$318.5M	2023-12-30	2026-02-18	10-K	0001100682-26-000022
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$619.6M	2022-12-31	2025-02-19	10-K	0001100682-25-000011
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$324.7M	2022-12-31	2025-02-19	10-K	0001100682-25-000011
32	current assets	us-gaap:AssetsCurrent	\$1.4B	2024-12-28	2026-02-18	10-K	0001100682-26-000022
33	current liabilities	us-gaap:LiabilitiesCurrent	\$994.1M	2024-12-28	2026-02-18	10-K	0001100682-26-000022
34	assets	us-gaap:Assets	\$8.2B	2023-12-30	2025-02-19	10-K	0001100682-25-000011
35	assets	us-gaap:Assets	\$7.6B	2022-12-31	2024-02-14	10-K	0001100682-24-000007
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,227,800	2026-01-24	2026-02-18	10-K	0001100682-26-000022
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,141,607	2025-01-25	2025-02-19	10-K	0001100682-25-000011